1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Millions of individuals in the United States require long-term treatment with an oral
anticoagulant. For decades, vitamin K antagonists were the only oral option available; …

Oral anticoagulants are commonly prescribed but high risk to cause adverse events. Skilled
drug interaction management is essential to ensure safe and effective use of these …

Concomitant use of direct oral anticoagulants (DOACs) and medications with
inhibition/induction effect on P‐gp/CYP3A might increase risk of bleeding/treatment failure …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

Cancer patients have an increased risk of developing venous thromboembolic events.
Anticoagulation management includes prophylactic or therapeutic doses of low molecular …

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in
the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus …

Importance Diltiazem, a commonly prescribed ventricular rate–control medication for
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …

Aims P‐glycoprotein (P‐gp) and CYP3A4‐interacting drugs influence plasma levels of non‐
vitamin K antagonist oral anticoagulants (NOACs). However, the clinical relevance is …

The non–vitamin K antagonist oral anticoagulant rivaroxaban is used in several
thromboembolic disorders. Rivaroxaban is eliminated via both metabolic degradation and …